MDGL

337.61

1.90% 6.29

Dopo l'orario di chiusura: 337.61

Madrigal Pharmaceuticals Inc (MDGL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MDGL Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$331.32

Aprire:

$331

Volume 24 ore:

769.60K

Relative Volume:

2.19

Capitalizzazione di mercato:

$7.25B

Reddito:

Utile/perdita netta:

$-510.45M

Rapporto P/E:

-17.55

EPS:

-19.24

Flusso di cassa netto:

$-455.82M

1 W Prestazione:

+55.02%

1M Prestazione:

+61.99%

6M Prestazione:

+46.89%

1 anno Prestazione:

+129.84%

Intervallo 1D:

$316.67

$337.63

Intervallo di 1 settimana:

$213.71

$337.63

Portata 52W:

$133.99

$337.63

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Nome

Madrigal Pharmaceuticals Inc

Settore

Healthcare (1182)

Industria

Biotechnology (671)

Telefono

404-380-9263

Indirizzo

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Dipendente

376

Cinguettio

@MadrigalPharma

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

MDGL's Discussions on Twitter

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-12-20	Reiterato	Oppenheimer	Outperform
2022-12-19	Reiterato	H.C. Wainwright	Buy
2022-12-19	Reiterato	Piper Sandler	Overweight
2022-12-19	Aggiornamento	Raymond James	Underperform → Mkt Perform
2022-07-08	Downgrade	B. Riley Securities	Buy → Neutral
2021-10-07	Iniziato	Jefferies	Buy
2021-08-06	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Ripresa	Goldman	Buy
2020-11-24	Ripresa	Evercore ISI	Outperform
2020-11-06	Reiterato	H.C. Wainwright	Buy
2020-07-31	Iniziato	Piper Sandler	Overweight
2020-06-05	Iniziato	BMO Capital Markets	Market Perform
2020-05-05	Iniziato	Chardan Capital Markets	Buy
2020-01-30	Iniziato	Canaccord Genuity	Buy
2020-01-09	Aggiornamento	UBS	Neutral → Buy
2019-11-07	Reiterato	H.C. Wainwright	Buy
2019-06-25	Iniziato	Stifel	Hold
2019-06-10	Aggiornamento	B. Riley FBR	Neutral → Buy
2019-02-28	Reiterato	H.C. Wainwright	Buy
2019-02-22	Iniziato	SVB Leerink	Outperform
2019-01-23	Iniziato	UBS	Neutral
2018-12-14	Iniziato	Wolfe Research	Outperform
2018-12-12	Iniziato	B. Riley FBR	Neutral
2018-11-19	Downgrade	Raymond James	Mkt Perform → Underperform
2018-11-16	Aggiornamento	Evercore ISI	In-line → Outperform
2018-09-04	Iniziato	Citigroup	Buy
2018-08-06	Downgrade	Goldman	Buy → Neutral
2018-06-28	Iniziato	Raymond James	Mkt Perform

Mostra tutto

Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie

11:35 AM

B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat

11:35 AM

Nov 04, 2024

Check Out What Whales Are Doing With MDGL - Benzinga

Nov 04, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High on Analyst Upgrade - MarketBeat

Nov 04, 2024

Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations - Yahoo Finance

Nov 04, 2024

What is Leerink Partnrs' Forecast for MDGL FY2028 Earnings? - MarketBeat

Nov 04, 2024

Emerald Advisers LLC Has $5.79 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat

Nov 04, 2024

Nov 03, 2024

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? - Benzinga

Nov 03, 2024

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha

Nov 03, 2024

Nov 02, 2024

(MDGL) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance

Nov 02, 2024

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - Simply Wall St

Nov 02, 2024

Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts - Yahoo Finance

Nov 02, 2024

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up - MSN

Nov 02, 2024

Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances - MSN

Nov 02, 2024

Nov 01, 2024

MDGL stock soars to 52-week high, reaching $299.99 By Investing.com - Investing.com South Africa

Nov 01, 2024

Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat - MSN

Nov 01, 2024

Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily

Nov 01, 2024

Madrigal Pharmaceuticals stock jumps on MASH drug hopes - Yahoo Finance

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 at UBS Group - MarketBeat

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Earnings Results, Beats Estimates By $2.02 EPS - MarketBeat

Nov 01, 2024

MDGL stock soars to 52-week high, reaching $299.99 - Investing.com

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Sees Strong Trading Volume After Strong Earnings - MarketBeat

Nov 01, 2024

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript - MSN

Nov 01, 2024

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug - Yahoo Finance

Nov 01, 2024